Allgens(SH:688613) Ge Long Hui A P P·2026-02-27 07:50Core Viewpoint - Aojing Medical (688613.SH) reported a strong performance in its 2025 annual earnings, with significant growth in both revenue and net profit, driven by strategic market initiatives and enhanced production capabilities [1] Financial Performance - The company achieved total operating revenue of 223.51 million yuan, representing a year-on-year increase of 8.48% [1] - The net profit attributable to the parent company was 13.15 million yuan, showing a remarkable year-on-year growth of 203.86% [1] Market Strategy - The orthopedic artificial bone procurement has provided the company with opportunities for continued clinical usage and further market share expansion [1] - The company has strengthened its production assurance system to reliably meet the increased demand resulting from procurement [1] - Aojing Medical has deepened its regional market strategy through refined management and targeted marketing strategies, continuously expanding its sales network [1] Market Position - The company's annual revenue demonstrates a steady growth trend, further consolidating its leading position in the niche market [1]